Last reviewed · How we verify
LIB003
At a glance
| Generic name | LIB003 |
|---|---|
| Also known as | lerodalcibep |
| Sponsor | LIB Therapeutics LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia (PHASE3)
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (PHASE3)
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (PHASE3)
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (PHASE3)
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (PHASE3)
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (PHASE3)
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (PHASE3)
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIB003 CI brief — competitive landscape report
- LIB003 updates RSS · CI watch RSS
- LIB Therapeutics LLC portfolio CI